
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Therapeutics is viewed favorably because detalimogene has a credible regulatory and commercial path in high-risk BCG-unresponsive NMIBC, supported by management’s confidence in accelerated approval and initial payer feedback that coverage is more likely if NCCN guidelines include the therapy. Its appeal is driven less by best-in-class efficacy than by practical advantages for community urology practices: simple administration, reduced workflow burden, and a tolerability profile with 91% of TRAEs Grade 1-2 and only 4.8% Grade 3 TRAEs. Although the pivotal dataset is still immature, AUA 2026 data showed a 54% CR anytime rate and 25% 12-month CR, while management believes ~$1B net sales could require about 10% share or ~2000 patients at parity pricing.
Bears say
enGene Therapeutics is facing a weaker fundamental setup because the pivotal LEGEND cohort has shown underwhelming durability, with the 12-month CR estimate at 25% after 32 newly assessed patients, and management has already reduced the workforce by about 50% and stopped enrollment in Cohorts 2a, 2b, and 3. The investment case now hinges on unproven assumptions that polidocanol can materially improve transfection and restore response consistency, yet the company still has no formal cash runway guidance despite reporting $285.2M of cash, cash equivalents, and marketable securities as of April 30, 2026. With clinical, regulatory, competitive, and financial risks all elevated, the stock looks vulnerable if the maturing data do not materially improve or if FDA and payer acceptance remains uncertain.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Engene Holdings Inc (ENGN) Forecast
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares